Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

Rhea-AI Summary

Eyenovia (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, will report its Q1 2024 financial results on May 15, 2024, after the market closes.

A conference call and webcast will follow at 4:30 p.m. ET to review the financial and operating results. Participants can join the call at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). Live and archived webcasts will be available on the investor relations page of Eyenovia's website.

Positive

• Eyenovia has two FDA-approved products and a late-stage asset in pediatric progressive myopia.
• A conference call and webcast will be held to discuss financial results, indicating transparency and engagement with investors.
• The live webcast will be archived for one year, providing continuous access to information.

Negative

• No preliminary financial data or guidance provided in the press release, leaving investors uncertain about performance expectations.
• The press release lacks specific details about revenue, earnings, and EPS for Q1 2024.

Company to host an investor conference call and webcast at 4:30pm EDT

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company will release financial results for the first quarter ended March 31, 2024 on Wednesday, May 15th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results.

Participants should dial 1-800-717-1738 (domestic) or 1-646-307-1865 (international).

To access the Call me™ feature, which avoids having to wait for an operator, click here.

A live webcast of the conference call will also be available here and on the investor relations page of the Company's corporate website at www.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery, which will be launched later this summer.

Eyenovia is also advancing late-stage development of medications in the Optejet device for myopia progression (MicroPine, partnered with Arctic Vision in China and South Korea) and other indications.

For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

FAQ

When will Eyenovia report its Q1 2024 financial results?

Eyenovia will report its Q1 2024 financial results on May 15, 2024, after the market closes.

What time is Eyenovia's Q1 2024 earnings conference call?

Eyenovia's Q1 2024 earnings conference call is scheduled for 4:30 p.m. ET.

How can I join Eyenovia's earnings call for Q1 2024 results?

You can join the call by dialing 1-800-717-1738 (domestic) or 1-646-307-1865 (international), or by using the Call me™ feature available through the provided link.

Where can I access the live webcast of Eyenovia's Q1 2024 earnings call?

The live webcast can be accessed on Eyenovia's investor relations page.

Will the webcast of Eyenovia's Q1 2024 earnings call be available after the event?

Yes, the webcast will be archived on Eyenovia's website for one year.